News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 11 - 12

Andao Pharma Announces Completion of Over RMB 400 Million Series C Financing

Recently, Hangzhou Andao Pharmaceutical Co., Ltd. announced the completion of a Series C financing round exceeding RMB 400 million. This round was invested in by Grand Pharma (with Huadong Medicine as a major LP), Taiping Medical Health Fund, C&D Emerging Investment, Hangzhou Taikun, Zhejiang Province "4+1" Biopharmaceutical and High-End Medical Device Industry Fund, Guangzhou Industrial Investment, Guangzhou Development District, Science and Technology Financial Holding, and Hangzhou Talent Fund, among others, with follow-on investments from existing shareholders including Efung...

浏览次数：6

查看详情>>

发布时间: 2025 - 11 - 03

Betta Pharmaceuticals and Shengsi Bio Reach Strategic Cooperation

Recently, Betta Pharmaceuticals and Shengsi Bio reached a comprehensive strategic cooperation agreement. Betta Pharmaceuticals will provide support to Shengsi Bio across R&D, clinical development, manufacturing, registration, and sales & marketing to facilitate the R&D, industrialization, and commercialization of related products. Additionally, the two companies signed a commercial cooperation agreement granting Betta Pharmaceuticals exclusive distribution rights for FRSW117 (a long-acting recombinant coagulation factor VIII-Fc fusion protein for injection) in the Greater China reg...

浏览次数：5

查看详情>>

发布时间: 2025 - 10 - 28

First under Restarted STAR Market 5th Criteria! OriginBio Debuts with "Rice Hematopoietic" Tech

On October 28, OriginBio officially listed on the Science and Technology Innovation Board (STAR Market) with the stock code 688765 and an IPO price of 29.06 yuan per share. This marks the first listing of an unprofitable enterprise under the STAR Market's Fifth Set of Listing Criteria since China Securities Regulatory Commission Chairman Wu Qing announced the restart of this policy at the Lujiazui Forum on June 18. It not only signifies a substantial breakthrough in institutional innovation on the STAR Market but also rewrites the global biopharmaceutical landscape with a single strai...

浏览次数：10

查看详情>>

发布时间: 2025 - 10 - 23

CoreRay’s 3 Key Products Secure EU CE Certification

Recently, three core interventional access products independently developed by CoreRay Medical have successfully obtained EU CE certification:Zhipeng Single-use Interventional MicrocatheterZhiguan Peripheral Vascular Microguide WireRuishen Balloon Dilatation CatheterThis marks CoreRay’s first EU CE certification since its founding, signifying international authoritative recognition of its R&D capabilities and quality system, and laying a solid foundation for entering the European and global markets.EU CE certification is a globally recognized gold standard for medical device safety and per...

浏览次数：5

查看详情>>